Post-Acute COVID-19 Vaccination Syndrome (PACVS) describes persistent, multi-system symptoms that begin within days to weeks of COVID-19 vaccination and last for months or years. It is also called post-COVID-19 vaccination syndrome (PCVS), post-vaccination syndrome (PVS) or, informally, "long vax".
Overlaps with Long COVID
PACVS and Long COVID are distinct clinical entities with overlapping biology. Long COVID follows infection, while PACVS follows vaccination without necessarily any prior infection. Both share fatigue, post-exertional malaise, brain fog and dysautonomia, and both are thought to involve spike protein.
Often presents as a known syndrome
PACVS can present as recognised diagnoses such as postural orthostatic tachycardia syndrome (POTS), small-fibre neuropathy or ME/CFS.
Severity varies widely
Some people keep up most daily activities. Others become partially or fully disabled.
Diagnosis is clinical
There is no single validated diagnostic test and no approved treatment. Research is focused on measurable markers that can tell PACVS apart from a normal vaccine response.
Symptoms
Fatigue & energy
- Profound fatigue unrelieved by rest
- Post-exertional malaise (PEM)
- Exercise intolerance
Neurological
- Brain fog
- Memory and concentration problems
- Neuropathic pain
- Small-fibre neuropathy
Cardiovascular
- Palpitations
- Chest pain
- Blood pressure changes
- Shortness of breath
Autonomic
- Orthostatic intolerance / POTS
- Dizziness on standing
- Temperature dysregulation
- Abnormal sweating
Sleep & mood
- Unrefreshing sleep
- Insomnia
- Anxiety
- Low mood
Other
- Gastrointestinal symptoms
- Joint and muscle pain
- Headache
- Skin reactions
Post-exertional malaise. It often appears 24–72 hours after the activity, which makes triggers hard to identify. Pacing, meaning managing activity to stay within your energy limits, is the main way to manage PEM.
Related conditions
PACVS often meets the criteria for one or more of these established diagnoses.
ME/CFS
Profound fatigue, post-exertional malaise, unrefreshing sleep and cognitive difficulties. Many people with PACVS meet ME/CFS criteria.
POTS
An autonomic disorder in which heart rate rises abnormally on standing, with dizziness, lightheadedness and fainting.
MCAS
Mast cells release excess mediators, causing flushing, hives, gastrointestinal symptoms and, at worst, anaphylaxis.
Small-fibre neuropathy
Damage to small nerve fibres that causes burning pain, tingling and numbness, and can affect autonomic function.
Testing and markers
No single test confirms PACVS. The markers below are being studied as parts of a multi-marker panel.
| Marker | Type | What it shows | Mechanism |
|---|---|---|---|
| Anti-spike (anti-S) antibodies | Serology | Show prior vaccination or infection. | — |
| Anti-nucleocapsid (anti-N) antibodies | Serology | Specific to infection, because current vaccines don't contain nucleocapsid. Anti-S positive with anti-N negative points away from infection-related illness. | — |
| GPCR / RAS autoantibodies | Serology | AT1-receptor and α2B-adrenergic receptor antibodies, linked to dysautonomia. | Autoimmunity |
| Circulating spike or S1 | Spike detection | Measured by ultrasensitive immunoassay or proteomics. | Persistent antigen |
| Extracellular-vesicle-bound spike | Spike detection | Spike carried on extracellular vesicles may indicate antigen that is still active. | — |
| Mass spectrometry: vaccine vs viral spike | Spike detection | Spike from mRNA vaccines carries two proline substitutions (K986P, V987P) that viral spike lacks, so mass spectrometry can in principle tell them apart. | — |
| Iron status | Metabolic | Ferritin and transferrin saturation. | — |
| Blood lactate | Metabolic | Lactate threshold arriving earlier during exercise. | Mitochondria & metabolism |
| CRP, IL-6 and other cytokines | Inflammatory | Systemic inflammation. | Immune dysregulation |
| Heart-rate variability | Functional | An indicator of autonomic function. | Autonomic & nerve |
| Exercise testing | Functional | 6-minute walk test or two-day CPET. | — |
| Quality-of-life scores | Functional | PAC-19QoL and similar instruments. | — |
Management
There is no cure yet. Care is individualised and often involves several specialists.
- Pacing to avoid triggering post-exertional malaise
- Symptom-targeted medication, such as heart-rate control for POTS
- Gentle physical therapy within the person's energy limits
- Strategies for cognitive symptoms
- Sleep, hydration and electrolyte balance
- Symptom diaries to identify patterns and triggers
Common questions
How is PACVS different from normal vaccine side effects?
Normal reactions such as a sore arm, mild fever or a few days of fatigue resolve within one to two weeks. PACVS involves persistent, often disabling symptoms that last months or years, and can meet criteria for ME/CFS, POTS or small-fibre neuropathy.
Is PACVS the same as Long COVID?
No, but the two overlap. Long COVID follows infection and PACVS follows vaccination. Both share core symptoms and many candidate mechanisms. Serology (anti-S positive, anti-N negative) helps separate PACVS from infection-related illness.
What causes PACVS?
Research points to several interacting mechanisms: persistent spike or S1 protein, immune dysregulation, GPCR and RAS autoantibodies, endothelial and clotting abnormalities, and mitochondrial dysfunction. Individual susceptibility may involve genetic, metabolic and physiological factors. See the seven mechanism groups →
Is there a test for PACVS?
There is no single validated test. Research proposes a multi-marker panel combining serology, spike detection, GPCR autoantibodies, metabolic markers and functional measures such as heart-rate variability and exercise testing. See biomarker alterations →
Key publications
Restoring trust in vaccination: listening to patients and acknowledging Post-Acute COVID Vaccine Syndrome
Halma M, Varon J · Frontiers in Medicine (2025)
Argues that PACVS overlaps substantially with Long COVID and proposes a biomarker framework built on serology, spike antigenemia and autoantibodies.
Breaking the silence: recognizing post-vaccination syndrome
Halma M, Varon J · Heliyon 11:e43478 (2025)
Argues that formally recognising post-vaccination syndrome is needed for affected people to receive care, and addresses the gap in diagnostic criteria.
Mitochondrial reactive oxygen species: a unifying mechanism in Long COVID and spike protein-associated injury
Lee E, Ozigbo AA, Varon J, Halma M, et al. · Biomolecules 15(9):1339 (2025)
Reviews mitochondrial ROS, impaired mitophagy and redox signalling as a driver shared by Long COVID and spike-associated injury.
The possible mechanistic basis of individual susceptibility to spike protein injury
Halma M, Vottero P, Thorp J, Peers T, Tuszynski J, Marik P · Advances in Virology (2025)
Explores the genetic and physiological factors that may explain why some people are more susceptible to spike-related pathology.
Exploring autophagy in treating SARS-CoV-2 spike protein-related pathology
Halma M, Marik P, Saleeby Y · Endocrine and Metabolic Science (2024)
Reviews autophagy-enhancing approaches, including fasting, spermidine and resveratrol, as ways to clear persistent spike.
Strategies for the management of spike protein-related pathology
Halma MTJ, Plothe C, Marik P, Lawrie TA · Microorganisms 11(5):1308 (2023)
Proposes management strategies for vaccine injury and Long COVID based on shared spike-mediated mechanisms.
Resources
React19
Patient-led support and advocacy organisation for people with post-vaccine injuries.
SpikeProtein.site
Resource on spike protein pathology, persistence and therapeutic approaches.
OSMF Research Platform
Open research tracker and biomarker atlases for Long COVID, PACVS and ME/CFS.
Vaccine Data Navigator
Data tools for exploring vaccine safety information.
This page is educational and does not provide medical advice. Consult a healthcare provider for diagnosis and treatment.